Development of a syphilis serum bank to support research, development, and evaluation of syphilis diagnostic tests in the United States

Diagn Microbiol Infect Dis. 2020 Jan;96(1):114913. doi: 10.1016/j.diagmicrobio.2019.114913. Epub 2019 Oct 24.

Abstract

The Centers for Disease Control and Prevention's (CDC) Division of STD Prevention, in collaboration with the Association of Public Health Laboratories (APHL), is developing a nationally available syphilis serum repository for research of Food and Drug Administration (FDA)-cleared or investigational syphilis diagnostic assays in the United States. State and local public health laboratories (PHL) submitted de-identified residual sera with information on collection date, volume, storage conditions, freeze-thaw cycles, PHL serology results, reported syphilis stage and demographic details if available. Previous test results were blinded and sera (N = 152 reported syphilis stage, N = 131 unknown status) were tested at CDC using five FDA-cleared and one investigational syphilis tests. Treponemal and nontreponemal test sensitivity ranged from 76.3-100% and 63.2-100%, respectively, among staged specimens. The conventional treponemal assays showed high concordance of 95.4%. By providing syphilis stage and comprehensive serological test data, developed repository may serve as a valuable resource for diagnostic test validation studies.

Keywords: Nontreponemal test; Serological diagnostic assay; Serum bank; Syphilis diagnostic assay; Syphilis serum repository; Syphilis stage; Treponemal test.

MeSH terms

  • Adult
  • Antibodies, Bacterial / blood*
  • Blood Banks*
  • Centers for Disease Control and Prevention, U.S.
  • Female
  • Humans
  • Male
  • Mass Screening / methods*
  • Sensitivity and Specificity
  • Syphilis / blood*
  • Syphilis / diagnosis
  • Syphilis Serodiagnosis*
  • Treponema pallidum
  • United States
  • Young Adult

Substances

  • Antibodies, Bacterial